Pemigatinib

Active Ingredient: Pemigatinib
Form: Oral tablet
Brand Name: Pemazyre
Generic Name: Peminib
Generic Manufacturer: Ziska Pharmaceuticals

Indications:
Pemazyre is indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement, as confirmed by diagnostic testing.

Dosage and Administration:
The recommended dose is 13.5 mg orally once daily, typically following a 21-day treatment cycle (e.g., 14 days on treatment followed by 7 days off). Dosage and treatment cycles may be adjusted based on clinical response and tolerability.

Common Side Effects:
Hyperphosphatemia, alopecia, stomatitis, diarrhea, fatigue, nausea, and dry mouth.

Storage:
Store below 30°C in a cool, dry place away from light. Keep out of reach of children.

Frequently Asked Questions

Q: What is the relationship between Pemazyre and Pemigatinib?
A: Pemazyre is the brand name registered by the original manufacturer. Pemigatinib is its active ingredient.

Q: Is the Pemazyre sold by Mediva Rx the original brand-name drug?
A: No. Mediva Rx offers a high-quality generic version manufactured by one of Bangladesh’s top 10 pharmaceutical companies. It contains the same active ingredient and therapeutic efficacy as the original, and is tested and approved by the Directorate General of Drug Administration (DGDA).

Q: Is the manufacturer of the Pemazyre generic reliable?
A: Yes. We work with Ziska Pharmaceuticals, one of Bangladesh’s leading pharmaceutical companies with certified R&D, production, and quality control facilities. They meet international GMP standards. You can purchase with confidence.

Disclaimer:
This information is for reference only. Treatment decisions should be made in consultation with your physician and based on the official medication guide and the latest medical research.

Drug Instructions (Package Insert):
Download Link